About Dexcom

Dexcom debuted their first ever Super Bowl commercial which calls for better care for people with diabetes who are still painfully pricking their fingers to measure their glucose levels.

The FDA cleared the Dexcom G6 Pro Continuous Glucose Monitoring (CGM) System for healthcare professionals to use with their patients, ages two years and up.  Dexcom G6 Pro is the first and only single use, professional CGM that gathers real-time glucose data over a 10-day period and offers both a blinded and unblinded mode.

The FDA permitted the marketing of the Dexcom G6 integrated continuous glucose monitoring (iCGM) system for determining glucose (sugar) levels in children aged two years and older and adults with diabetes. The Dexcom G6 is indicated by the FDA for use as both a standalone CGM and for integration into automated insulin dosing (AID) systems. 

Android users now have access to the free app for the Dexcom G5 Mobile CGM System. At the time, Dexcom G5 Mobile CGM System was the first and only CGM platform available for Android in the United States.

Centers for Medicare & Medicaid Services (CMS) Classify Therapeutic Continuous Glucose Monitors (CGM) as "Durable Medical Equipment". Dexcom was the first CGM system that falls within this classification.

The proposed non-adjunctive indication for the Dexcom G5 Mobile CGM system is approved by the FDA. This indication designates the G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions.

The Dexcom G5 Mobile CGM System became the first and only fully mobile CGM system to allow adults and children as young as two years old the convenience of monitoring their glucose levels from a compatible smart device. It also gave patients the option to safely share their glucose data with others.

The Share feature for the G4 PLATINUM CGM System gave patients the option to share their glucose information with up to five followers through Dexcom Share and Follower apps on their smart devices via a secure wireless connection.

The G4 PLATINUM's overall accuracy and ease of use set a new standard for commercially available CGMs, making the Dexcom G4 PLATINUM the most-advanced CGM system available at the time.

The SEVEN® PLUS System launched as Dexcom’s third generation device designed to help people with diabetes better manage their glucose levels.

Study data presented by the Juvenile Diabetes Research Foundation (JDRF) at the 44th annual meeting of the European Association for the Study of Diabetes (EASD) showed the use of CGM to be effective in the management of type 1 diabetes.

Dexcom launched the SEVEN^® CGM System, the first CGM system approved for up to seven days of continual use.

Dexcom launched the first generation continuous glucose monitor designed to help people with diabetes more conveniently and effectively manage their blood sugar levels.

The initial public offering (IPO) for Dexcom was announced on the NASDAQ Stock Market under DXCM.

Three generations of Dexcom’s long-term implantable sensors were developed and studied in humans.

Dexcom was founded based on the groundbreaking research of Dr. Stuart J. Updike and George P. Hicks in 1967—implantable, long-performing glucose sensors that the body would not reject. Dr. Updike joined Dexcom that year to continue CGM innovation.